Meyka Pro banner
Biofrontera Inc.

Biofrontera Inc. (NASDAQ: BFRIW) Stock Competitors & Peer Comparison

See BFRIW's competitors and their performance on the NASDAQ and across the wider stock market.

BFRIWNASDAQ
HealthcareMedical - Pharmaceuticals
$0.02
$0.00(1.46%)
U.S. Market opens in 4h 8m

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for BFRIW and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BFRIW$0.02-1.46%11.4M-0.03-$0.60N/A
RPRX$58.60-0.56%25.9B11.13$5.25+1.59%
CORT$114.10-0.66%11.9B315.11$0.35N/A
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
LQDA$66.92-2.16%5.9B477.71$0.14N/A
KNSA$77.76-1.98%5.9B85.82$0.90N/A
PBH$46.85+0.82%2.1B10.17$4.42N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
LTGO$21.69-9.35%1.4BN/AN/AN/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Royalty Pharma plc (NASDAQ: RPRX)

BFRIW vs RPRX Comparison September 2026

Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRIW stands at 11.4M. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while RPRX trades at $58.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRIW currently has a P/E ratio of -0.03, whereas RPRX's P/E ratio is 11.13. In terms of profitability, BFRIW's ROE is -1.28%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, BFRIW is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions